Subscribe

Articles

The Impact of New Driver Mutations on Treatment of NSCLC
IWTI Best Practices in Lung Cancer Navigation
The Impact of New Driver Mutations on Treatment of NSCLC
By Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators
Videos
Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC Read More ›
Educating Patients About the Need to Wait for Biomarker Test Results
IWTI Best Practices in Lung Cancer Navigation
Educating Patients About the Need to Wait for Biomarker Test Results
By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators, Video
Videos
Waiting for biomarker test results ensures the best outcomes in NSCLC. Read More ›
Explaining the Treatment Trajectory in NSCLC
IWTI Best Practices in Lung Cancer Navigation
Explaining the Treatment Trajectory in NSCLC
By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators, Video
Videos
Describing the road map of the cancer care journey in NSCLC. Read More ›
Real-World Use of Chemotherapy During End of Life in Patients with Metastatic Breast Cancer
Breast Cancer
Web Exclusives
Use of chemotherapy near the end of life in patients with metastatic breast cancer may potentially negatively impact quality of life. Read More ›
A Randomized Controlled Trial Evaluating Low-Dose Tamoxifen for Breast Cancer Prevention and Mammographic Density Reduction
Breast Cancer
Web Exclusives
Low-dose tamoxifen could be used for prevention and to increase sensitivity of mammograms in premenopausal women. Read More ›
Pandemic Impact on Breast Cancer Screening and Health Maintenance
Breast Cancer
Web Exclusives
Researchers report on early results from an effort to develop a predictive model and targeted strategies for communication and intervention for cancer screening during the COVID-19 pandemic. Read More ›
Cost-Effectiveness of Ribociclib for Hormone Receptor–Positive HER2-Negative Advanced Breast Cancer
Breast Cancer
Web Exclusives
Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer. Read More ›
Reflecting on Advances in NSCLC Treatment Over the Past 10 Years
IWTI Best Practices in Lung Cancer Navigation
Reflecting on Advances in NSCLC Treatment Over the Past 10 Years
By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators, Video
Videos
The use of targeted agents and immunotherapy has transformed the treatment of NSCLC Read More ›
Counseling Patients and Their Families on Treatment Options in NSCLC
IWTI Best Practices in Lung Cancer Navigation
Counseling Patients and Their Families on Treatment Options in NSCLC
By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators, Video
Videos
Encouraging shared decision making by NSCLC by educating and counseling patients and their families Read More ›

Page 82 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?